Keyword: Erez Vigodman

Teva promised investors it was pulling in top talent when it hired new CEO Kåre Schultz last fall. And to do that, it put down top dollar.

Especially after the week Teva’s had, it may need to pay up—big time—to land a CEO that can help it turn its fortunes.

More uncertainty has roiled Teva, as the company indicated it would eliminate up to 350 production workers in Israel.

Teva confirms that it's not only looking for an outsider to lead the company. It wants a seasoned pharma CEO.

Yet another key Teva exec could be bowing out in the company’s time of need—and that’s CFO Eyal Desheh.

Teva contends that Mexican generics buy Rimsa sold defective, illegal products and lied about it. But a new memo from Mexico’s drug regulator doesn't help its case.

Teva execs may have zeroed in on their first big revamp move since CEO Erez Vigodman's sudden exit.

So long, Erez Vigodman. After a brutal 2016 and start to 2017 for Teva, the company’s CEO is stepping down.

On Monday at the J.P. Morgan Healthcare Conference, Teva CEO Erez Vigodman explained just how the company arrived at the off-base guidance it cut last week by more than $1 billion.

Teva's generics CEO, Siggi Olafsson, is jumping ship at a critical time, and analysts fear that the $40.5 billion Actavis integration will go off the rails.